Clinical Trials Logo

Triple-hit Lymphoma (THL) clinical trials

View clinical trials related to Triple-hit Lymphoma (THL).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01742988 Completed - Lymphoma Clinical Trials

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Start date: December 2012
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. Fimepinostat (CUDC-907) is a multi-targeted agent designed to inhibit phosphoinositide 3-kinase (PI3K)and histone deacetylase (HDAC). The study is designed to assess the safety, the maximum tolerated dose, the recommended phase 2 dose (RP2D), pharmacokinetics and the anti-cancer activity of oral fimepinostat in combination with 1 or more anti-cancer regimens.